Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20605220 | 0.94 | CYP3A4 (0.37) | HRH3POLBALDH1A1KCNH2MEN1 | |
| SCHEMBL18954051 | 0.84 | CYP3A4 (0.37) | HRH3POLBALDH1A1KCNH2MEN1 | |
| SCHEMBL28690594 | 0.78 | HRH3 (0.53) | HRH3POLBALDH1A1KDM4ETSHR | |
| SCHEMBL18587273 | 0.76 | ERCC1 (0.44) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL20605083 | 0.76 | LPL (0.35) | MEN1KMT2A | |
| SCHEMBL24745864 | 0.74 | ALDH1A1 (0.57) | HRH3POLBALDH1A1KDM4E | |
| SCHEMBL17045814 | 0.74 | KMT2A (0.43) | HRH3ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL20605102 | 0.74 | HRH3 (0.51) | HRH3POLBALDH1A1KDM4EKCNH2 | |
| SCHEMBL14470730 | 0.74 | HIF1A (0.39) | — | |
| SCHEMBL15941075 | 0.73 | CYP4F2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4493182-A1 | PHENYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | Huyabio International, LLC (US) | 2025-01-22 | — | — | EP | disclosed |
| WO-2023177593-A1 | PHENYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | HUYABIO INTERNATIONAL, LLC (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023177593-A1 | PHENYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | HUYABIO INTERNATIONAL, LLC (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230286925-A1 | PHENYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | HUYABIO INTERNATIONAL, LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230286925-A1 | PHENYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | HUYABIO INTERNATIONAL, LLC | 2023-09-14 | — | — | US | disclosed |
| US-11174250-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2021-11-16 | — | — | US | disclosed |
| US-20190119264-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | Propellon Therapeutics Inc. (CA) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174250-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | HRH3 1224/4885POLB 3493/4885ALDH1A1 3365/4885 |
| US-20190119264-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | WDR5, WDR82, WDR1 | HRH3 2541/4885POLB 3119/4885ALDH1A1 3617/4885 |
| US-20230286925-A1 | PHENYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | WDR5, MLLT1, WDR1 | HRH3 1426/4885POLB 3513/4885ALDH1A1 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.